USFDA gives approves to Lupin’s cholesterol-lowering drug

November 23, 2023
Insights, News
36 secs read

Source: FinancialExpress

Lupin Limited on Tuesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg.

The approval has been granted to market a generic equivalent of Livalo Tablets, 1 mg, 2 mg, and 4 mg, of Kowa Company Limited. The product will be manufactured at Lupin’s Pithampur facility in India.

Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:

Adults with primary hyperlipidemia.
Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).

Pitavastatin Tablets (RLD Livalo) had estimated annual sales of USD 298 million in the U.S. (IQVIA MAT September 2023).

Pharmaways

Pharmaways Global Private Limited is a company established in 2022. Headed by a group of professionals with over 25 years of experience. A team of professionals who have excelled in their respective fields of Pharma, Legal & Information Technology. We have global exposure and hands-on experience of the global Pharma industry. We are in pursuit of bringing the global Pharma Industry on a platform where they can connect, collaborate and work towards mutual growth. We have taken a step into the future by innovating a technology that will help global Pharma players to empower, excel and accelerate in their business. A platform that has been developed exclusively for the Pharma fraternity. We are a New Delhi based company with overseas offices in America and the United Kingdom.